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of some other unknown cofactor that is not es­
sential for GBS is required. A third possibility is 
that fear of the adverse consequences of ZIKV 
infection led to fewer conceptions or a greater 
number of pregnancy terminations in 2016. Rou­
tinely collected data are not yet complete enough 
to determine whether birth rates fell or abortion 
rates increased in 2016 (Section 6 in the Supple­
mentary Appendix). However, since any changes 
in the number of live births would be small, this 
hypothesis cannot be the principal reason why 
few cases of microcephaly were reported in the 
northeast region in 2016.
Among these hypotheses, the first seems to 
be the most plausible — that is, both ZIKV and 
chikungunya viruses are important causes of GBS, 
but among the arboviruses circulating in Brazil, 
only ZIKV causes microcephaly and other neuro­
logic disorders after infection during pregnancy. 
However, the three possibilities are not mutually 
exclusive, and none can be ruled out with the 
present data. Further investigations are needed 
— aided by more sensitive and specific diagnos­
tic tools and the careful interpretation of surveil­
lance data — to clarify the causal links between 
arbovirus infections, GBS, and microcephaly in 
Brazil.
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Bezlotoxumab and Recurrent Clostridium difficile Infection
To the Editor: Wilcox et al. (Jan. 26 issue)1 
found that the risk of recurrent Clostridium difficile 
infection was nearly 40% lower among patients 
treated with bezlotoxumab than among those 
who received standard care. In the accompany­
ing editorial, Bartlett speculates about whether 
bezlotoxumab, although clearly efficacious, will be 
cost­effective.2 We think this discussion would 
be incomplete without citing the efficacy and rela­
tively low cost of probiotics in the prevention of 
C. difficile infection. In multiple systematic reviews 
that included meta­analyses of randomized, con­
trolled trials in which the rates of both initial 
and recurrent infections were measured, probi­
otics were shown to have safety and impressive 
efficacy, with a relative risk reduction of more 
than 50% in the prevention of C. difficile infection 
in high­risk immunocompetent populations.3,4 Pro­
biotics have also been shown to be cost­effective.5 
Given their substantial efficacy and greatly reduced 
cost, we urge providers to review the literature 
and consider the use of probiotics for immuno­
competent patients who are receiving antibiotics 
and are at high risk for C. difficile infection.
Anna Maw, M.D.
University of Colorado 
Denver, CO 
anna . maw@ ucdenver . edu
Nicole Shen, M.D.
Weill Cornell Medical College 
New York, NY
Prashanth Francis, M.D.
University of Colorado 
Denver, CO
No potential conflict of interest relevant to this letter was re­
ported.
1. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for 
prevention of recurrent Clostridium difficile infection. N Engl J Med 
2017; 376: 305­17.
The New England Journal of Medicine 
Downloaded from nejm.org on August 22, 2018. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 376;16 nejm.org April 20, 20171594
2. Bartlett JG. Bezlotoxumab — a new agent for Clostridium dif-
ficile infection. N Engl J Med 2017; 376: 381­2.
3. Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics 
in hospitalized adults prevents Clostridium difficile infection: 
a systematic review with meta­regression analysis. Gastroenter­
ology 2017 February 9 (Epub ahead of print).
4. Lau CS, Chamberlain RS. Probiotics are effective at prevent­
ing Clostridium difficile­associated diarrhea: a systematic review 
and meta­analysis. Int J Gen Med 2016; 9: 27­37.
5. Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ. 
Cost­effectiveness analysis of the use of probiotics for the preven­
tion of Clostridium difficile­associated diarrhea in a provincial 
healthcare system. Infect Control Hosp Epidemiol 2016; 37: 1079­86.
DOI: 10.1056/NEJMc1702531
To the Editor: In the analysis of the effects of a 
given agent on the recurrence of C. difficile infec­
tion, patients need to have been cured of their 
initial infection before acquiring a recurrent in­
fection. Furthermore, patients might die during 
follow­up; thus, death is a classic competing event 
for cure and recurrent C. difficile infection.1­3 Wilcox 
et al. censored data from patients without a clin­
ical cure at the date of infusion of the medication. 
Conditioning on the future violates one principle 
of time­to­event analyses4; censoring competing 
events leads to bias (an overestimation of the risk 
of infection recurrence).
We emphasize that “get cured, stay alive, and 
remain free of recurrent infection over time” is a 
more relevant end point for patients with C. diffi-
cile infection. Using a multistate model, we have 
schematically displayed the competing risk bias 
and reconstructed our proposed end point (Fig. 1). 
Our analysis indicated the possibility that although 
both active­treatment groups had a lower risk of 
recurrent infection, the probability of being 
cured, alive, and free of recurrent infection is 
lower in the actoxumab–bezlotoxumab group 
than in the placebo group for the first 5 weeks. 
Such time­dependent effects are hidden in the 
original analysis but are highly relevant from the 
patients’ perspective and should therefore be made 
transparent.
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The authors reply: Maw et al. quote two sys­
tematic reviews and meta­analyses, both focused 
on the prevention of primary rather than recurrent 
C. difficile infection; recurrent C. difficile infection 
is the primary outcome that is reduced by bezlo­
toxumab. Others have concluded that there is 
little evidence to support the use of probiotics to 
prevent recurrent C. difficile infection,1,2 and a recent 
systematic review concluded that they are not 
more effective than placebo for the prevention of 
primary infection in elderly hospitalized patients.3 
Meta­analyses of the efficacy of probiotics aggre­
gate data on very different preparations and vary­
ing dosages. It is notable that by far the largest 
randomized, controlled trial of probiotics to pre­
vent C. difficile infection showed no benefit.4
Maw et al. also referred to cost­effectiveness. 
In a post­hoc analysis of the data from our trials, 
treatment with bezlotoxumab was found to reduce 
30­day C. difficile infection–associated hospital re­
admissions in the overall population and among 
patients who were at high risk for infection re­
currence.5 In the subgroup of participants who 
were hospitalized at the time of randomization 
(68% of the modified intention­to­treat popu­
lation), 4.0% of bezlotoxumab recipients had a 
C. difficile infection–associated readmission, as 
compared with 9.6% of placebo recipients (dif­
ference, −5.7 percentage points; 95% confidence 
interval, −8.8 to −2.7).
In their analysis, Sommer et al. demonstrate 
that bezlotoxumab treatment results in a rate of 
recurrent C. difficile infection that is substantially 
lower than that associated with placebo. They 
propose an end    point of “get cured, stay alive, 
and remain free of recurrent infection over time” 
to address bias that may have been introduced 
by failure to achieve initial clinical cure and by 
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deaths that occurred during follow­up. We also 
considered the effect of these factors on the pri­
mary end point (see the Sensitivity Analyses sec­
tion of the Supplementary Appendix, available 
with the full text of our article at NEJM.org). 
Because the rates of competing events were simi­
lar for bezlotoxumab and placebo recipients, it is 
not surprising that the bezlotoxumab effect size 
was consistent between the multistate model 
analysis (Fig. 1B and 1C of their letter) and the 
analysis in our article. Despite the limitations of 
the multistate model (which assumes a constant 
failure rate during follow­up after initial clinical 
cure), the results align with our predefined pri­
mary end point. Moreover, the rates of recurrent 
infection from the Kaplan–Meier analysis are 
similar, given the censoring, to those among 
participants with initial clinical cure — another 
clinically important end point.
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Figure 1. Patient-Relevant End Points and Analysis  
of Trials for the Prevention of Recurrent Clostridium 
difficile Infection.
Panel A shows a multistate model suitable for the 
present scenario, with an initial infusion state, a cure 
state, a state of recurrent Clostridium diff icile infection 
(rCDI), and competing event states (including, e.g., 
treatment failure and death). The direction of arrows 
indicates the potential transitions between the states 
determined by transition hazards. For a simulated data 
set, the following rates per patient-day, which are as-
sumed to be time-constant for illustration purposes, 
were reconstructed with values taken from the article 
by Wilcox et al.: a cure rate of 0.082 for actoxumab– 
bezlotoxumab, 0.089 for bezlotoxumab, and 0.089 for 
placebo; a competing event rate before cure of 0.029 
for actoxumab–bezlotoxumab, 0.022 for bezlotoxumab, 
and 0.021 for placebo; a rate of recurrent infection of 
0.003 for actoxumab–bezlotoxumab, 0.003 for bezlo-
toxumab, and 0.005 for placebo; and a competing event 
rate after cure of 0.003 for actoxumab–bezlotoxumab, 
0.003 for bezlotoxumab, and 0.003 for placebo. To show 
the competing risk bias, we censored data from patients 
who did not have clinical cure at day 1. Panel B shows 
the probability of having a sustained cure (i.e., cure and 
no recurrent infection, a secondary end point used by 
Wilcox et al. at week 12) and being alive as the proposed 
time-dependent patient-relevant quantity. The curves 
for actoxumab–bezlotoxumab and placebo cross be-
cause placebo is associated with a higher cure rate but 
also with a higher rate of recurrent infection. Panel C 
shows the probability of recurrent infection based on 
the modified intention-to-treat population (primary 
end point used by Wilcox et al.), which is easily and 
 adequately estimated on the basis of this model. The 
probability after 12 weeks coincides approximately with 
the raw proportions: 119 of 773 (15%) for actoxumab–
bezlotoxumab, 129 of 781 (17%) for bezlotoxumab, and 
206 of 773 (27%) for placebo. When data from patients 
are censored at day 1, the risks are overestimated.
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The editorialist replies: Probiotics were not in­
cluded in my editorial because evidence support­
ing their use to prevent C. difficile infection seemed 
inadequate. Admittedly, there are some controlled 
trials that support the use of probiotics,1 but others 
show no significant benefit.2 A review of guide­
lines for the management of C. difficile infection 
from five international societies shows that either 
they have not endorsed the use of probiotics for 
this purpose or they have failed to address probi­
otics in their recommendations.3 To my knowl­
edge, none of these agents have been approved by 
the Food and Drug Administration (FDA) for this 
indication. Thus, there appears to be a lack of 
convincing and consistent support from trials, 
C. difficile infection guidelines from five learned 
societies, or FDA reviews. Note that this does not 
mean that they do not work — only that this 
recommendation needs better and more consis­
tent evidence for support. Also worrisome is the 
fact that “probiotics” is a broad term that in­
cludes many different products that may differ 
substantially in their results, making product 
specificity a likely need.
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“Zombie” Outbreak Caused by Synthetic Cannabinoid
To the Editor: Adams et al. (Jan. 19 issue)1 de­
scribe an outbreak of synthetic cannabinoid 
AMB­FUBINACA intoxication that was identified 
with the use of a new approach that involved pre­
dicting and synthesizing analytical standards 
of possible cannabinoid analogues before their 
emergence in markets.1,2 This method is effective 
for detecting new synthetic drugs that have never 
been reported. However, since there are numer­
ous potential derivatives for every illicit drug, 
characterizing them fully in clinical laboratories 
is impractical.
All the synthetic cannabinoids that the au­
thors mention contain structural motifs of their 
raw materials, indole or indazole. Because there 
are no indole or indazole rings in common psy­
choactive substances such as amphetamines, co­
caine, and tetrahydrocannabinol, the presence of 
fragment ions of indole and indazole derivatives 
(e.g., C9H6NO
+ and C8H5N2O
+) might make mass 
spectrometry a suitable qualitative screening test 
for AMB­FUBINACA and other new synthetic can­
nabinoids.3­5 After qualitative screening of spe­
cific motif fragment ions in clinical laboratories, 
the results could be confirmed in reference labo­
ratories by the approach presented by Adams et al.
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